Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process clearer to the public (1"The Rose Sheet" June 15, 2009). The task force held two public meetings and accepted comments through Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings, with draft recommendations expected by January.

More from Archive

More from HBW Insight